ERBB2 and cancer: This applies to patients with biologically aggressive tumors (e.g., HER2-positive or high-proliferation cancers) as well as those with more favorable profiles, provided that perioperative complications are actively minimized and transition to oncology is planned before surgery [6,7,8,9,15,23].